ADC Therapeutics SAADCT
Oncology40 cited findings · profile updated 2026-08-24
1.04 USDnot live — refreshed daily
About ADC Therapeutics SA
ADC Therapeutics SA (ADCT) is an oncology research site. In the LOTIS-5 trial, a complete response rate of ~40% was observed, compared to ~27% for the comparator. The median PFS in LOTIS-5 was 6.14 months, while for R-GemOx it was 4.73 months. The overall response rate in LOTIS-5 was 58%, with a complete response rate of 40% and a partial response rate of 19%. For R-GemOx in LOTIS-5, the overall response rate was 45%, with a complete response rate of 27% and a partial response rate of 19%. The median duration of response in LOTIS-5 was 9.20 months, compared to 7.66 months for R-GemOx.
In the LOTIS-7 trial, the overall response rate was 95%, with a complete response rate of 81% and a partial response rate of 14%. For 150 µg/kg ZYNLONTA in LOTIS-7, the overall response rate was 86%, with a complete response rate of 75% and a partial response rate of 11%. The total overall response rate in LOTIS-7 was 90%, with a complete response rate of 78% and a partial response rate of 12%. For relapsed patients receiving 120 µg/kg ZYNLONTA in LOTIS-7, the overall response rate was 100%, with a complete response rate of 93% and a partial response rate of 7%. For primary refractory patients receiving 120 µg/kg ZYNLONTA in LOTIS-7, the overall response rate was 86%, with a complete response rate of 57%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Complete Response Rate | ~40% vs ~27% (LOTIS-5) | ADC Therapeutics SA — SEC 8-K (2026-08-13), p.10 |
| Median PFS | 6.14 months vs 4.73 months (LOTIS-5) | ADC Therapeutics SA — SEC 8-K (2026-08-13), p.10 |
| Overall Response Rate | 58% vs 45% (LOTIS-5) | ADC Therapeutics SA — SEC 8-K (2026-08-13), p.14 |
| Median Duration of Response | 9.20 months vs 7.66 months (LOTIS-5) | ADC Therapeutics SA — SEC 8-K (2026-08-13), p.15 |
| Overall Response Rate | 95% (LOTIS-7) | ADC Therapeutics SA — SEC 8-K (2026-08-13), p.24 |
| Complete Response Rate | 81% (LOTIS-7) | ADC Therapeutics SA — SEC 8-K (2026-08-13), p.24 |
Key projects
- LOTIS-5
The complete response rate in LOTIS-5 was ~40%, compared to ~27% for the comparator.
- LOTIS-7
The overall response rate in LOTIS-7 was 95%, with a complete response rate of 81%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →